Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Science of the Total Environment|December 31, 2020
Neonicotinoids in the agroecosystem: In-field long-term assessment on honeybee colony strength and microbiomeD Alberoni, R Favaro, L Baffoni, et al.
International Journal of Food Sciences and Nutrition|September 6, 2012
Synbiotic yogurt consumption by healthy adults and the elderly: the fate of bifidobacteria and LGG probiotic strainM Granata, G Brandi, A Borsari, et al.
Dental Materials : Official Publication of the Academy of Dental Materials|November 1, 1993
Antibacterial effectiveness of dentin bonding systemsC Prati, F Fava, D Di Gioia, et al.
Journal of Applied Microbiology|September 14, 2007
Selection and characterization of aerobic bacteria capable of degrading commercial mixtures of low-ethoxylated nonylphenolsD Di Gioia, A Michelles, M Pierini, et al.
The Italian Journal of Biochemistry|January 1, 1994
Regulation of dihydrodipicolinate synthase and diaminopimelate decarboxylase activity in Bacillus stearothermophilusA Selli, F Crociani, D Di Gioia, et al.
British Journal of Cancer|February 4, 2015
Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increaseD Di Gioia, P Stieber, G P Schmidt, et al.
Beneficial Microbes|November 14, 2015
Effect of dietary supplementation of Bifidobacterium and Lactobacillus strains in Apis mellifera L. against Nosema ceranaeL Baffoni, F Gaggìa, D Alberoni, et al.
Journal of Hazardous Materials|August 19, 2014
Bioavailability and biological effect of engineered silver nanoparticles in a forest soilS Carbone, L Vittori Antisari, F Gaggia, et al.
Beneficial Microbes|January 31, 2018
Impact of beneficial bacteria supplementation on the gut microbiota, colony development and productivity of Apis mellifera LD Alberoni, L Baffoni, F Gaggìa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2010
A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancerV Heinemann, D Di Gioia, U Vehling-Kaiser, et al.
Pageof 3